绝经后乳腺癌患者的辅助双膦酸盐治疗
Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.
作者信息
Gnant Michael
机构信息
Universitátsklinikfür Chirurgie, Medizinische Universität Wien, Austria.
出版信息
Breast Care (Basel). 2010;5(5):298-304. doi: 10.1159/000322099. Epub 2010 Oct 29.
Abstract
Adjuvant bisphosphonate therapy is increasingly used in postmenopausal breast cancer patients. This is based on level-one evidence that bisphosphonates, particularly zoledronic acid, can effectively prevent cancer treatment-induced bone loss in breast cancer patients receiving estradiol-lowering endocrine therapies such as aromatase inhibitors. Furthermore, emerging data from large clinical trials suggest that additional anticancer benefits can be derived due to a positive impact on the bone marrow microenvironment.
摘要
辅助性双膦酸盐治疗在绝经后乳腺癌患者中越来越常用。这是基于一级证据，即双膦酸盐，尤其是唑来膦酸，能有效预防接受降低雌二醇的内分泌治疗（如芳香化酶抑制剂）的乳腺癌患者出现癌症治疗引起的骨质流失。此外，大型临床试验的新数据表明，由于对骨髓微环境有积极影响，还能带来额外的抗癌益处。
相似文献
1
Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.绝经后乳腺癌患者的辅助双膦酸盐治疗
Breast Care (Basel). 2010;5(5):298-304. doi: 10.1159/000322099. Epub 2010 Oct 29.
2
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.接受辅助性乳腺癌治疗的绝经后女性癌症治疗引起的骨质流失的管理：Z-FAST更新
Semin Oncol. 2006 Apr;33(2 Suppl 7):S13-7. doi: 10.1053/j.seminoncol.2006.03.022.
3
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.对接受芳香化酶抑制剂治疗的早期乳腺癌女性的骨质流失进行管理。
Clin Breast Cancer. 2007 Dec;8 Suppl 1:S22-34. doi: 10.3816/cbc.2007.s.009.
4
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.唑来膦酸可预防接受激素受体阳性乳腺癌辅助内分泌治疗的绝经前女性发生癌症治疗引起的骨质流失：来自奥地利乳腺癌和结直肠癌研究组的报告
J Clin Oncol. 2007 Mar 1;25(7):820-8. doi: 10.1200/JCO.2005.02.7102. Epub 2006 Dec 11.
5
Current and future status of adjuvant therapy for breast cancer.乳腺癌辅助治疗的现状与未来发展态势
Cancer. 2003 Feb 1;97(3 Suppl):880-6. doi: 10.1002/cncr.11124.
6
Role of bisphosphonates in postmenopausal women with breast cancer.双膦酸盐类药物在绝经后乳腺癌女性中的作用。
Cancer Treat Rev. 2014 Apr;40(3):476-84. doi: 10.1016/j.ctrv.2013.07.003. Epub 2013 Jul 29.
7
Skeletal health in breast cancer survivors.乳腺癌幸存者的骨骼健康。
Maturitas. 2017 Nov;105:78-82. doi: 10.1016/j.maturitas.2017.08.008. Epub 2017 Aug 18.
8
Anticancer activity of bisphosphonates in breast cancer.双膦酸盐类药物在乳腺癌中的抗癌活性。
Anticancer Agents Med Chem. 2012 Feb;12(2):114-22. doi: 10.2174/187152012799014931.
9
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.优化接受内分泌治疗的乳腺癌患者的双膦酸盐治疗
Semin Oncol. 2004 Dec;31(6 Suppl 12):23-30. doi: 10.1053/j.seminoncol.2004.09.023.
10
Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.芳香酶抑制剂相关性骨丢失的治疗选择。
Endocr Metab Immune Disord Drug Targets. 2022;22(3):259-273. doi: 10.2174/1871530321666210809153152.
引用本文的文献
1
Osteooncology - Specific Aspects in Breast Cancer Patients.骨肿瘤学——乳腺癌患者的特定方面
Breast Care (Basel). 2010;5(5):288-289. doi: 10.1159/000321963. Epub 2010 Oct 26.
本文引用的文献
1
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.唑来膦酸对局部晚期乳腺癌患者播散肿瘤细胞的影响：一项开放标签、随机、2 期临床试验。
Lancet Oncol. 2010 May;11(5):421-8. doi: 10.1016/S1470-2045(10)70054-1. Epub 2010 Mar 31.
2
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.唑来膦酸治疗骨转移膀胱癌的前瞻性、随机、安慰剂对照试验。
Int J Clin Oncol. 2010 Aug;15(4):382-9. doi: 10.1007/s10147-010-0074-5. Epub 2010 Apr 1.
3
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.唑来膦酸联合新辅助化疗对肿瘤反应的影响：乳腺癌中直接抗肿瘤活性的探索性证据。
Br J Cancer. 2010 Mar 30;102(7):1099-105. doi: 10.1038/sj.bjc.6605604. Epub 2010 Mar 16.
4
Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.双膦酸盐在预防疾病复发中的作用：当前的结果和正在进行的试验。
Curr Cancer Drug Targets. 2009 Nov;9(7):824-33. doi: 10.2174/156800909789760267.
5
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.绝经前乳腺癌的内分泌治疗加唑来膦酸
N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285.
6
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.利塞膦酸盐预防原发性乳腺癌化疗绝经前女性骨质流失的III期随机、安慰剂对照、双盲试验。
J Clin Oncol. 2009 Mar 1;27(7):1047-53. doi: 10.1200/JCO.2008.19.1783. Epub 2008 Dec 15.
7
Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.三年口服阿仑膦酸钠辅助治疗的十年随访显示，其对早期乳腺癌患者骨质疏松有显著预防作用。
J Clin Oncol. 2008 Sep 10;26(26):4289-95. doi: 10.1200/JCO.2007.15.4997.
8
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.地诺单抗用于接受辅助性芳香化酶抑制剂治疗的非转移性乳腺癌患者的随机试验。
J Clin Oncol. 2008 Oct 20;26(30):4875-82. doi: 10.1200/JCO.2008.16.3832. Epub 2008 Aug 25.
9
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.绝经前早期乳腺癌患者辅助内分泌治疗联合唑来膦酸：ABCSG-12骨密度亚研究的5年随访
Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.
10
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.唑来膦酸可预防早期乳腺癌绝经前女性在接受辅助化疗时出现骨质流失。
J Clin Oncol. 2008 Oct 10;26(29):4739-45. doi: 10.1200/JCO.2008.16.4707. Epub 2008 Aug 18.
Zotero 插件